Originally published in Citeline on 21 Feb 2025.

In part 6 of this Scrip Asks series, Dr. Tomasz Kostrzewski, CSO at CN Bio, joins 140 other biopharma leaders, who share their views on key therapeutic area advances to look out for. They also discuss multiple scientific fields that are opening up new avenues for treatment.

“These are exciting times for our industry, with more new therapies making it to market each year to transform patient lives. At the same time, many therapeutic developers continue to struggle with the spiralling cost to develop a drug candidate through to market,” observed Tomasz Kostrzewski, chief scientific officer of CN Bio. “Around 90% of drugs that make it into the clinic still ultimately fail, and addressing this hurdle is a key focus for the industry. Many of these later stage failures arise due to a lack of human-relevant data during preclinical development, but how do we solve this?”

Kostrzewski predicted a rise in tools to ensure clinical plans are informed by more accurate preclinical data: “New approach methodologies (NAMs) are already helping to revolutionize how we approach drug discovery, and will be a crucial growth area moving into 2025. Developed as viable, cost-saving and oftentimes more effective alternatives to existing methods, technologies such as organ-on-a-chip are helping therapeutic developers to progress their candidates to the clinic with more confidence than ever before. As we look towards the year ahead, we’re excited to see NAMs continue to go from strength to strength, enabling rapid and efficient therapeutic advancements.”

“Greater speed and efficiency will be paramount in 2025 as the life sciences community continues its push to develop new therapies and modalities faster. Partnerships will be key to this work. Companies will need collaborators that enable their ideas with solutions that deliver results with ease,” said Joe Fox, president of Beckman Coulter Life Sciences. “Many labs will require application expertise as they automate workflows to balance growing demands on their team. Others will seek new insights from small particles, like extracellular vesicles, as exciting new technologies revolutionize this workflow. The company that offers flexibility, scalability, and sustainability will emerge as the preferred partner.”

View the full article here.